Telmisartan/hydrochlorothiazide

Telmisartan/hydrochlorothiazide, sold under the brand name Micardis HCT among others, is a fixed-dose combination medication used to treat high blood pressure.[2] It is a combination of telmisartan an angiotensin II receptor antagonist with hydrochlorothiazide a diuretic.[2] It may be used if telmisartan by itself is not sufficient.[5] It is taken by mouth.[5]

Telmisartan/hydrochlorothiazide
Combination of
TelmisartanAngiotensin II receptor antagonist
HydrochlorothiazideThiazide diuretic
Clinical data
Trade namesMicardisPlus, Micardis HCT, PritorPlus, others
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only) [1]
  • US: ℞-only [2]
  • EU: Rx-only [3][4]
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC40H38ClN7O6S2
Molar mass812.36 g·mol−1
3D model (JSmol)
  (verify)

Common side effects include dizziness, upper respiratory tract infections, nausea, diarrhea, and tiredness.[2] Severe side effects may include kidney problems, electrolyte problems, and allergic reactions.[2] Use during pregnancy may harm the baby.[2] Telmisartan works by blocking the effects of angiotensin II while hydrochlorothiazide works by decreasing the kidneys' ability to retain water.[2]

The combination was approved for medical use in the United States in November 2000,[6][7] and in the European Union in April 2002.[3][4] The combination is on the World Health Organization's List of Essential Medicines.[8] It is available as a generic medication.[5]

References
  1. "MicardisPlus 40 mg/12.5 mg Tablets - Summary of Product Characteristics (SmPC)". (emc). 28 May 2020. Retrieved 23 November 2020.
  2. "Micardis HCT- telmisartan and hydrochlorothiazide tablet". DailyMed. 27 August 2020. Retrieved 4 October 2020.
  3. "MicardisPlus EPAR". European Medicines Agency (EMA). Retrieved 4 October 2020.
  4. "PritorPlus EPAR". European Medicines Agency (EMA). Retrieved 4 October 2020.
  5. British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 178. ISBN 9780857113382.
  6. "Drug Approval Package: Micardis HCT (telmisartan/hydrochlorothiazide) NDA #021162". U.S. Food and Drug Administration (FDA). 11 March 2004. Retrieved 4 October 2020.
  7. "Hydrochlorothiazide and telmisartan Uses, Side Effects & Warnings". Drugs.com. Retrieved 29 October 2019.
  8. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.